This announcement is a separate document:
国浩律师（杭州）事务所关于奥锐特药业股份有限公司2022年限制性股票激励计划第一个解除限售期解除限售及调整回购价格相关事项的法律意见书
Legal Opinion of Attorney Guohao (Hangzhou) Firm on matters relating to the first lifting of the sales restriction period and the adjustment of repurchase prices in the 2022 restricted stock incentive plan of Orient Pharmaceutical Co., Ltd.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.